SWOT Analysis (Sanofi)

Fourth largest company by prescription sales .

Market leadership in vaccines with Sanofi Pasteur Oncology pipeline has
more than 15 molecules.
Usage of renewable energy for manufacturing High operating cost which incur high amount of expense.
Site. Patent expired of blockbuster drugs (Plavix and Lovenox)
Very good in conducting Social Responsibilities Low R&D productivity but high R&D investment
like tuberculosis awareness programmes.
diabetes awareness programmes
Experience of working in International market.

Strength Weakness

Opportunity Threat
Can capture entire African Market and expansion to new geographical
areas. Global economic slowdown as major of company’s revenue is based
Genzyme has given its considerable presence in uncommon diseases. on Exports.
Population growth and increase of purchasing power of developing Chance of losing market because of quality Issues (Combiflam
countries. withdrawal)
Marketing agreements with leading companies in developing and Stringent regulations in new drug development
developed countries. Increase in generic competition
Sanofi has agreed to buy Belgian biotech company to enrich its reach